AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 131 min read$TAK

Ricci Gabriele sold $429K of TAK

Ricci Gabriele (Chief Data & Tech. Officer) sold 25,088 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 ($0.43M total) on 2026-08-10.

Original reporting
SEC EDGAR · Ricci Gabriele
Published Aug 13, 2026, 1:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TAK
Neutral
medium confidence
Mentioned
$TAK
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

The newest fact is the dated open-market sale of 25,088 shares at $17.10, totaling about $429,005, with holdings after the sale of 171,654 shares.

02

Market read

Traders may note insider selling for sentiment monitoring, but there is no accompanying operational or guidance catalyst in the text.

03

What to watch

The filing does not state a 10b5-1 plan, but it also provides no reason for the sale, and insider sales are common even during positive company periods.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12, transaction dated 2026-08-10

Background

The article is a SEC Form 4 insider transaction disclosure for Takeda (TAK) by Ricci Gabriele, Chief Data and Tech Officer.

Company-level read

Ticker impact

$TAKNeutralMedium confidence
Context

Takeda disclosed a Form 4 showing Chief Data and Tech Officer Ricci Gabriele sold 25,088 shares at $17.10 on 2026-08-10.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional signal from the filing alone.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan stated and no accompanying operational or guidance change. The disclosed size is moderate relative to a large pharma, so the market reaction is typically muted unless part of a broader pattern.

Market effects

Sector

Insider selling headlines can slightly weigh on large-cap pharma sentiment, but this specific filing does not indicate sector-wide change.

Regional

No clear regional spillover; this is company-specific insider activity.

Global

Minimal global relevance; no deal, trial, or regulatory development is disclosed.

Counterpoint

What could challenge this read

The sale may be unrelated to fundamentals (tax, diversification, or pre-planned liquidity needs), so it should not be treated as a bearish signal by default.

Key entities

  • issuer
    TAK

    Takeda Pharmaceutical Co Ltd, the Form 4 issuer.

  • insider
    Ricci Gabriele

    Chief Data and Tech Officer who sold shares via open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TAK insider trading history →

Related articles

AUG 24
$TAKMedAI 8/10

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Takeda (TYO:4502/NYSE:TAK) announced Japan's approval of ORZEYFUL (oveporexton) for treating narcolepsy type 1 (NT1) in adults. The drug, discovered by Takeda, is the first to target the underlying cause of NT1. Approval follows successful Phase 3 trials showing significant symptom improvements. ORZEYFUL is also approved in China and the U.S.

thestarphoenix.com2 min
AUG 21
$TAKMedAI 8/10

Takeda Q1 adjusted EPS beats estimates despite slight sales dip

Takeda Pharmaceutical reported Q1 adjusted EPS of $0.48, beating estimates by 23.08%, with sales of $7.655 billion, up 8.42% from expectations but down slightly year-over-year. The company maintained its FY2026 guidance, noting currency headwinds and pipeline advancements, including regulatory approvals for ORZEYFUL and rusfertide. Positive Phase 3 results for zasocitinib in psoriasis were also announced, with submissions planned for regulatory approval.

scanx.trade3 min
AUG 18
$TAKMedAI 8/10

This Newly Approved Narcolepsy Drug Is the First to Target the Sleep Disorder’s Root Cause Rather Than Its Symptoms

The FDA approved Orzeyful, a narcolepsy type 1 drug by Takeda, targeting the root cause by mimicking orexin. Clinical trials showed improved wakefulness, sleep, and fewer cataplexy episodes. Takeda's CEO called it a new chapter for treatment. The drug may also have applications for ADHD and Parkinson's. According to experts, more research is needed, as not all patients lack orexin.

smithsonianmag.com4 min
AUG 8
$TAKMedAI 8/10

Takeda (TAK) Q1 2026 Earnings Call Transcript

Takeda (TAK) reported Q1 2026 revenue of JPY 1.22 trillion, up 10.2% on an actual FX basis but down 0.5% at constant rates, citing Vyvanse generic erosion offset by core brands. Core operating profit was JPY 358.9 billion and core EPS JPY 154. FY2026 guidance: revenue JPY 4.64 trillion, core op profit JPY 1.16 trillion, adjusted FCF JPY 650-750B. Orzeyful China approved; U.S./Japan expected in Q2 2026.

fool.com7 min